A recent study indicates that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who end conventional lifestyle plans.
Published data in a prominent medical journal points out that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Individuals buying such medications need to be cognizant of the danger of fast rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to starting weight in about a year and a half.
Analyzing Therapies
The research, which examined dozens of trials involving thousands of participants, contrasted the results of these new drugs with conventional dieting.
Scientists point out that people who lose weight through dieting usually see a slower creep back—approximately 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Nutrition scientists suggest the mode of action of the injections is key to understanding the accelerated weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels far above than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement means appetite is uncontrolled, making overeating much more probable."
An Ongoing Disease?
Health authorities suggest the injections for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, due to the high risk of relapse, the therapy is often life-long.
This view is echoed by pharmaceutical companies, who state that the findings "underscore the long-term nature of obesity," similar to managing diseases like diabetes.
Patient Testimonies
Individuals who have come off the jabs report a intense resurgence of cravings.
"It felt as if a trigger flipping and you're instantly starving," described an individual.
This challenge is exacerbated if users have not developed sustainable dietary or behavioural modifications during treatment.
Significant Adoption
Recent estimates suggest that millions of people in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Use is higher among females than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Finally, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a permanent solution and long-term success relies on integrated lifestyle management.
